These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 7259534)

  • 1. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H
    Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 9. Plafibride treatment and serum lipids in hyperlipoproteinemias.
    Rodriguez F; López IM; Jover E
    J Med; 1987; 18(3-4):153-63. PubMed ID: 3323393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Improvement in diabetes control by treatment with bezafibrate].
    Rüth E; Vollmar J
    Dtsch Med Wochenschr; 1982 Oct; 107(39):1470-3. PubMed ID: 6749468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H; Klein HJ
    Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Neuman MP; Kurlat MI; Neuman J
    Curr Med Res Opin; 1983; 8(5):358-67. PubMed ID: 6839800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.